美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

百济神州

337.89

+17.525.47%

盘后：337.890.00000.00%19:11 EST

成交量：66.66万

成交额：2.24亿

市值：402.09亿

市盈率：577.88

高：340.81

开：329.29

低：328.75

收：320.37

52周最高：385.22

52周最低：174.74

股本：1.19亿

流通股本：7,564.19万

量比：1.89

换手率：0.88%

股息：- -

股息率：- -

每股收益(TTM):0.5847

每股收益(LYR):-6.1240

净资产收益率：1.81%

总资产收益率：1.69%

市净率：9.74

市盈率(LYR):-55.17

数据加载中...

总览公司新闻资讯公告

百济神州(06160)授出合共5.33万股美国存托股份受限制股份单位

百济神州新型BCL2抑制剂百悦达（索托克拉片）在中国获得上市许可

老虎资讯综合

又出血液肿瘤新药！百济神州股价微跌，“创新药一哥”能再造爆款？

重磅，百济神州又一款1类新药迎来新进展

北京药研汇

千亿出海潮：中国创新药企驶入全球深水区

从量变到质变，政策协同、技术爆发与产业重构的三重跃迁

百济神州盘中异动早盘急速上涨5.44%报327.95美元

百济神州BG - C0902启动Ⅰ期临床适应症为晚期实体瘤

百济神州BCL-2抑制剂“索托克拉”获批上市

医药魔方Info

展望2026年：我国医药行业将正式步入创新药大时代

国内商保发展和集采优化创新药产业链持续活跃

【医疗与消费周度观点】创新药行业研发突破与市场演进的并行

大胡子产业经济

【兴证医药】医药生物行业2026年年度策略：创新迈入新篇章，国际化驶向新征程

兴证医药健康

21专访丨高特佳投资副总经理于建林：锚定下一代疗法创新药行业走向价值深化

21世纪经济报道

双总裁时代的百济神州还有哪些故事可讲？

国际金融报

TIGIT抗体再折戟：胃癌三期失败，免疫治疗前路何在？

午后突发！港股通创新药ETF（520880）跌2.77%创阶段新低，康方生物、百济神州等大权重龙头领跌

中信证券：医保谈判成功率创近年新高，关注创新药企

药价登记，出海新支点

药视声Medispace

19种药品纳入首版商保目录，5款CAR-T疗法集体入围，影响有多大？

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ONC/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":337.89,"timestamp":1767992400000,"preClose":320.37,"halted":0,"volume":666560,"hourTrading":{"tag":"盘后","latestPrice":337.89,"preClose":337.89,"latestTime":"19:11 EST","volume":1741,"amount":588266.48,"timestamp":1768003880090},"delay":0,"floatShares":75641900,"shares":119000000,"eps":0.584711,"marketStatus":"休市中","change":17.52,"latestTime":"01-09 16:00:00 EST","open":329.29,"high":340.81,"low":328.745,"amount":224442778.449807,"amplitude":0.03766,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.584711,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1768208400000},"marketStatusCode":7,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":320.37,"preHourTrading":{"tag":"盘前","latestPrice":329.2,"preClose":320.37,"latestTime":"09:25 EST","volume":17713,"amount":5678005.77105,"timestamp":1767968700004},"postHourTrading":{"tag":"盘后","latestPrice":337.89,"preClose":337.89,"latestTime":"19:11 EST","volume":1741,"amount":588266.48,"timestamp":1768003880090},"volumeRatio":1.887327,"impliedVol":0.3822,"impliedVolPercentile":0.0279},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":75641900,"roa":"1.69%","roe":"1.81%","lyrEps":-6.124009,"volumeRatio":1.887327,"shares":119000000,"dividePrice":0,"high":340.81,"amplitude":0.03766,"preClose":320.37,"low":328.745,"week52Low":174.74,"pbRate":"9.74","psRate":"8.09","week52High":385.22,"institutionHeld":0,"latestPrice":337.89,"eps":0.584711,"divideRate":0,"volume":666560,"delay":0,"ttmEps":0.584711,"open":329.29,"prevYearClose":303.81,"prevWeekClose":311.02,"prevMonthClose":303.81,"prevQuarterClose":303.81,"fiveDayClose":311.02,"twentyDayClose":322.68,"sixtyDayClose":320.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-06","symbol":"ONC","fiscalQuarterEnding":"2025/09","expectedEps":0.72,"name":null,"time":"盘后","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":1.09},{"date":"2025-08-30","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756540800000,"name":null,"time":"盘前","dateTimestamp":1756526400000,"actualEps":null},{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盘前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.6667,"hold":0.0417,"sell":0.0417,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":24,"updateTime":1764046800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2026-01-08","current":577.584482,"percent":0.965432,"low":-217.585346,"twenty":-87.567781,"median":-40.685969,"eighty":-21.954664,"high":609.337035,"avg":-9.906374,"sd":191.510369,"marketCap":36945367429},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-18","current":-87.653233,"twenty":-47.435675,"median":-39.313748,"eighty":-23.176246,"marketCap":34392148550},{"date":"2025-07-25","current":-89.648478,"twenty":-48.541013,"median":-39.640999,"eighty":-23.189441,"marketCap":35175014575},{"date":"2025-08-01","current":-91.060669,"twenty":-60.626235,"median":-39.865155,"eighty":-23.250607,"marketCap":35729110635},{"date":"2025-08-08","current":-184.757225,"twenty":-63.824658,"median":-40.051934,"eighty":-23.50984,"marketCap":32820458238},{"date":"2025-08-15","current":-191.818248,"twenty":-64.911375,"median":-40.112152,"eighty":-23.522344,"marketCap":34074785315},{"date":"2025-08-22","current":-194.469228,"twenty":-72.041871,"median":-40.222554,"eighty":-23.535152,"marketCap":34545708113},{"date":"2025-08-29","current":-184.552827,"twenty":-72.8475,"median":-40.343171,"eighty":-23.581122,"marketCap":32784148770},{"date":"2025-09-05","current":-197.417514,"twenty":-73.864189,"median":-40.425269,"eighty":-23.723244,"marketCap":35069444682},{"date":"2025-09-12","current":-208.147892,"twenty":-74.224679,"median":-40.801852,"eighty":-23.82061,"marketCap":36975599617},{"date":"2025-09-19","current":-212.503459,"twenty":-75.66857,"median":-40.932054,"eighty":-23.865007,"marketCap":37749326897},{"date":"2025-09-26","current":-203.715512,"twenty":-76.587723,"median":-41.008162,"eighty":-23.928977,"marketCap":36188227257},{"date":"2025-10-03","current":-213.916471,"twenty":-77.910534,"median":-41.112345,"eighty":-23.950329,"marketCap":38000335866},{"date":"2025-10-10","current":-208.109485,"twenty":-81.639564,"median":-41.598105,"eighty":-24.044918,"marketCap":36968777077},{"date":"2025-10-17","current":-197.090466,"twenty":-85.2662,"median":-41.668284,"eighty":-24.084563,"marketCap":35011347487},{"date":"2025-10-24","current":-192.138725,"twenty":-87.584871,"median":-41.753651,"eighty":-24.09529,"marketCap":34131715179},{"date":"2025-10-31","current":-191.016991,"twenty":-89.061223,"median":-41.811067,"eighty":-24.120226,"marketCap":33932449287},{"date":"2025-11-07","current":-207.03708,"twenty":-89.680521,"median":-41.96845,"eighty":-24.175905,"marketCap":36778273935},{"date":"2025-11-14","current":594.631071,"twenty":-89.43801,"median":-41.811067,"eighty":-24.044918,"marketCap":40761959883},{"date":"2025-11-21","current":563.847015,"twenty":-89.201535,"median":-41.753651,"eighty":-23.82061,"marketCap":38651712910},{"date":"2025-11-28","current":549.835185,"twenty":-89.104768,"median":-41.685343,"eighty":-23.530029,"marketCap":37691201965},{"date":"2025-12-05","current":534.967794,"twenty":-89.063642,"median":-41.61723,"eighty":-23.184163,"marketCap":36672042310},{"date":"2025-12-12","current":517.921144,"twenty":-88.590694,"median":-41.129457,"eighty":-23.039198,"marketCap":35503494432},{"date":"2025-12-19","current":495.611986,"twenty":-88.19516,"median":-41.047814,"eighty":-22.787779,"marketCap":33974201659},{"date":"2025-12-26","current":503.21518,"twenty":-87.945005,"median":-40.950457,"eighty":-22.473183,"marketCap":34495400571},{"date":"2026-01-02","current":490.430192,"twenty":-87.636143,"median":-40.899758,"eighty":-22.105685,"marketCap":33618989662},{"date":"2026-01-08","current":538.955032,"twenty":-87.567781,"median":-40.685969,"eighty":-21.954664,"marketCap":36945367429}],"updateTime":1767992338423},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2601787308","title":"百济神州(06160)授出合共5.33万股美国存托股份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2601787308","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601787308?lang=zh_cn&edition=fundamental","pubTime":"2026-01-07 16:49","pubTimestamp":1767775792,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年12月31日，董事会及╱或董事会薪酬委员会根据2016期权及激励计划的条款授予155名承授人合共5.33万股美国存托股份受限制股份单位。该等受限制股份单位相当于69.32万股股份，约占本公告之日公司发行股份总数的0.04%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","ONC","LU1251922891.USD","BK1583","LU1969619763.USD","BK4585","LU0588546209.SGD","BK1161","LU1719994722.HKD","BK1500","688235","BK1588","LU2328871848.SGD","LU1770034418.SGD","LU0307460666.USD","LU1303224171.USD","06160","BK4526","BK4139"],"gpt_icon":0},{"id":"1170001608","title":"百济神州新型BCL2抑制剂百悦达（索托克拉片）在中国获得上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1170001608","media":"老虎资讯综合","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170001608?lang=zh_cn&edition=fundamental","pubTime":"2026-01-06 19:02","pubTimestamp":1767697320,"startTime":"0","endTime":"0","summary":"1月6日，$百济神州$宣布，其自研的1类新药新型BCL2抑制剂百悦达获得国家药品监督管理局附条件批准，用于治疗既往接受过至少包含布鲁顿酪氨酸激酶抑制剂在内的一种系统治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤成人患者，以及既往接受过至少两种系统性治疗的复发或难治性套细胞淋巴瘤成人患者。基于此次获批，索托克拉将为已接受过BTK抑制剂治疗的CLL/SLL患者带来新的治疗选择，更使其成为国内首款且唯一可用于治疗MCL的BCL2抑制剂。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百济神州新型BCL2抑制剂百悦达（索托克拉片）在中国获得上市许可","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1770034418.SGD","LU2328871848.SGD","688235","BK1588","BK0239","BK1583","LU1719994722.HKD","LU1969619763.USD","LU1303224171.USD","06160","BK4139","BK4526","BK1161","LU0307460666.USD","ONC","BK1500","BK4585","LU1251922891.USD","LU0588546209.SGD"],"gpt_icon":0},{"id":"2601889690","title":"又出血液肿瘤新药！百济神州股价微跌，“创新药一哥”能再造爆款？","url":"https://stock-news.laohu8.com/highlight/detail?id=2601889690","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601889690?lang=zh_cn&edition=fundamental","pubTime":"2026-01-06 18:29","pubTimestamp":1767695361,"startTime":"0","endTime":"0","summary":"血液恶性肿瘤患者迎来新药。1月5日，国家药品监督管理局官网显示，国内“创新药一哥”百济神州-U（688235.SH）的BCL-2（B细胞淋巴瘤-2）抑制剂索托克拉片双适应证获批上市。上述两项适应证分别为用于治疗既往接受过治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）成人患者；用于治疗既往接受过抗CD20治疗和BTKi治疗的套细胞淋巴瘤（MCL）成人患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601063610323958.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1500","06160","BK1161","688235","LU2328871848.SGD","LU0588546209.SGD","LU1719994722.HKD","BK4585","BK1583","BK1588","LU1303224171.USD","LU1251922891.USD","159992","LU1770034418.SGD","BK1574","BK4526","LU0307460666.USD","06978","ONC","BK0239","LU1969619763.USD","BK4139"],"gpt_icon":0},{"id":"2601917854","title":"重磅，百济神州又一款1类新药迎来新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2601917854","media":"北京药研汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601917854?lang=zh_cn&edition=fundamental","pubTime":"2026-01-06 08:01","pubTimestamp":1767657678,"startTime":"0","endTime":"0","summary":"特应性皮炎，这一慢性、复发性、炎症性皮肤病，近年来在全球范围内发病率持续上升，给患者的生活质量带来了严重影响。BGB-45035是百济神州开发的一款IRAK4 CDAC，正被研究用于治疗各类自身免疫性疾病。据报道，该药物具有潜力诱导更深、更快的IRAK4降解，并且细胞因子抑制作用更强，是百济神州在自有CDAC平台上研发的第二款靶向降解剂。IRAK4作为先天免疫关键靶点，近年来受到多家药企关注。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106081138a6f7b13c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106081138a6f7b13c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","06160","BK4526","BK4139","ONC"],"gpt_icon":0},{"id":"2601854186","title":"千亿出海潮：中国创新药企驶入全球深水区","url":"https://stock-news.laohu8.com/highlight/detail?id=2601854186","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601854186?lang=zh_cn&edition=fundamental","pubTime":"2026-01-06 07:13","pubTimestamp":1767654792,"startTime":"0","endTime":"0","summary":"中国药企不仅成为全球医药研发体系中不可忽视的力量，也在重新定义自身在国际市场上的角色。从首付款到里程碑款的持续流入，标志着中国创新药的全球开发已实质性推进至临床中后期乃至商业化阶段。这意味着中国药企不再只是技术提供方，而是以平等伙伴身份参与全球价值创造与分配。中国药企在跨境谈判、知识产权布局、国际争议解决等方面经验仍显不足。锻造出海“航母舰队”中国创新药的集体出海，离不开产业集群的支撑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106071431a6f7878c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106071431a6f7878c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4526","CXO","02509","00013","01167","BMS","06160","BK4585","BK4139","01801","01541"],"gpt_icon":0},{"id":"2601585325","title":"从量变到质变，政策协同、技术爆发与产业重构的三重跃迁","url":"https://stock-news.laohu8.com/highlight/detail?id=2601585325","media":"新快报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601585325?lang=zh_cn&edition=fundamental","pubTime":"2026-01-06 06:58","pubTimestamp":1767653908,"startTime":"0","endTime":"0","summary":"2025年医药健康盘点2025年，中国医药健康领域迎来从“量变”到“质变”的关键跃升，是政策、技术与产业协同成效。同期，诺和诺德口服司美格鲁肽获FDA批准用于减重，成为全球首个口服GLP-1减重药。资本与研发加速布局凸显赛道热度，印证GLP-1已成为代谢疾病核心资产。但同时，超10家企业申报司美格鲁肽生物类似药，同质化竞争风险加剧。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106070629a6f781ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106070629a6f781ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","06160","BK1161","02359","AZN","01801","03696","ONC","BK1574"],"gpt_icon":1},{"id":"2601854164","title":"百济神州盘中异动 早盘急速上涨5.44%报327.95美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601854164","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601854164?lang=zh_cn&edition=fundamental","pubTime":"2026-01-05 22:31","pubTimestamp":1767623486,"startTime":"0","endTime":"0","summary":"北京时间2026年01月05日22时31分，百济神州股票出现波动，股价急速上涨5.44%。截至发稿，该股报327.95美元/股，成交量2.6425万股，换手率0.02%，振幅2.00%。百济神州股票所在的生物技术行业中，整体跌幅为0.32%。百济神州有自己的团队进行全球临床试验。截至2024年，其核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的60%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105223126a49f633b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105223126a49f633b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","ONC","BK4526","BK4139"],"gpt_icon":0},{"id":"2601854118","title":"百济神州BG - C0902启动Ⅰ期临床 适应症为晚期实体瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2601854118","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601854118?lang=zh_cn&edition=fundamental","pubTime":"2026-01-05 18:30","pubTimestamp":1767609000,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，广州百济神州生物制药有限公司的一项探索靶向 EGFR×MET 的抗体偶联药物 BG - C0902 单药治疗和与其他治疗药物联合用药治疗晚期实体瘤患者的安全性、耐受性、药代动力学、药效学和初步抗肿瘤活性的1a/1b 期研究已启动。BG - C0902 为生物制品，适应症为晚期实体瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105183358a6f59bce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105183358a6f59bce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","LU0251142724.SGD","LU2211817866.USD","LU0471298694.HKD","LU0471298777.SGD","LU0742534661.SGD","BK4189","ONC","BK4585","LU0048573561.USD","BK4588","LU0385154629.USD","BK4139","LU0251131958.USD","BG","LU2360106947.USD"],"gpt_icon":0},{"id":"2601800005","title":"百济神州BCL-2抑制剂“索托克拉”获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2601800005","media":"医药魔方Info","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601800005?lang=zh_cn&edition=fundamental","pubTime":"2026-01-05 18:19","pubTimestamp":1767608340,"startTime":"0","endTime":"0","summary":"1 月 5日，NMPA 官网显示，百济神州BCL-2抑制剂“索托克拉”两项适应症中国获批上市，适用于治疗既往接受过治疗的慢性淋巴细胞白血病/ 小淋巴细胞淋巴瘤成人患者，以及治疗既往接受过抗CD20治疗和BTKi治疗的套细胞淋巴瘤成人患者。索托克拉是百济神州开发的一款强效、高选择性BCL-2抑制剂，其设计旨在产生更深、更持久的靶点抑制。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-01-05/doc-inhfhavn6767115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1251922891.USD","BK0239","LU1303224171.USD","BK4526","LU1719994722.HKD","LU1770034418.SGD","LU0307460666.USD","BK1588","BK1500","LU2328871848.SGD","ONC","688235","BK4585","BK1161","06160","BK4139","LU0588546209.SGD","LU1969619763.USD","BK1583"],"gpt_icon":0},{"id":"2601925008","title":"展望2026年：我国医药行业将正式步入创新药大时代","url":"https://stock-news.laohu8.com/highlight/detail?id=2601925008","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601925008?lang=zh_cn&edition=fundamental","pubTime":"2026-01-05 13:27","pubTimestamp":1767590866,"startTime":"0","endTime":"0","summary":"展望2026年，有机构表示，我国医药生物行业将正式步入创新药大时代。该机构认为，2026年创新药将逐渐占据我国医药生物行业的主要地位，医保商保的互补结合将长期打开支付空间的天花板，创新药将持续蓬勃发展。根据梳理，2026年伊始，已经有多家药企公告创新药临床进展情况。据悉，该药上市申请于2025年4月获CDE受理并被纳入优先审评审批。2025年9月，安尼妥单抗在HER2阳性胃癌适应症的头个新药上市申请获NMPA受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105120700a49d38d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105120700a49d38d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","ONC","BK1574","09966","06978","01093","02171"],"gpt_icon":0},{"id":"2593477930","title":"国内商保发展和集采优化 创新药产业链持续活跃","url":"https://stock-news.laohu8.com/highlight/detail?id=2593477930","media":"金证研","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593477930?lang=zh_cn&edition=fundamental","pubTime":"2025-12-24 21:11","pubTimestamp":1766581900,"startTime":"0","endTime":"0","summary":"随着国内商保发展和集采优化，创新药产业链高景气有望延续。当前支持创新药产业发展已成为政策导向，2025年北京、上海、重庆、四川等多地出台相关政策，推动创新药行业高质量发展。近日，2026年医保药品目录和商保药品目录发布，首次在基本医保目录之外增设商保创新药目录。创新药长期产业趋势确定，在国内政策支持以及美联储进入降息周期的背景下，全球创新药研发持续活跃，2026年还有大量BD落地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224211713a6ca8bf6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224211713a6ca8bf6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2778985437.USD","LU1794554557.SGD","01801","LU1720050803.USD","LU0540923850.HKD","LU2476274720.SGD","LU1961090484.USD","LU0634319403.HKD","LU0348783233.USD","LU2399975544.HKD","LU2488822045.USD","01276","LU2476274308.USD","LU0417516902.SGD","LU0417516571.SGD","LU0348766576.USD","IE00B5MMRT66.SGD","BK1161","ONC","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU0348767384.USD","LU0348784397.USD","LU0561508036.HKD","LU0348825331.USD","09926","LU0348827113.USD","BK1574","LU0348735423.USD","LU0417516738.SGD","06978","01877"],"gpt_icon":0},{"id":"2594405038","title":"【医疗与消费周度观点】创新药行业研发突破与市场演进的并行","url":"https://stock-news.laohu8.com/highlight/detail?id=2594405038","media":"大胡子产业经济","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594405038?lang=zh_cn&edition=fundamental","pubTime":"2025-12-24 15:55","pubTimestamp":1766562917,"startTime":"0","endTime":"0","summary":"投资要点医疗新观察创新药行业研发突破与市场演进的并行创新药物是指具有自主知识产权专利的药品，需通过双盲随机对照试验验证有效性与安全性，研发过程呈现高投入、长周期、高风险特点，通常涉及靶向治疗、基因编辑等前沿技术，区别于仅需完成药学质量一致性和生物等效性试验的仿制药。未来，我国创新药行业同时面临多种机遇和挑战。首次同步发布的商保创新药目录纳入了19种药品，标志着多层次医疗保障体系取得实质性突破。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224155732a47254ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224155732a47254ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4526","BK4139","BK4585","01877"],"gpt_icon":0},{"id":"2593779374","title":"【兴证医药】医药生物行业2026年年度策略：创新迈入新篇章，国际化驶向新征程","url":"https://stock-news.laohu8.com/highlight/detail?id=2593779374","media":"兴证医药健康","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593779374?lang=zh_cn&edition=fundamental","pubTime":"2025-12-24 14:51","pubTimestamp":1766559113,"startTime":"0","endTime":"0","summary":"兴业证券医药小组近期，我们发布了《医药生物行业2026年年度策略：创新迈入新篇章，国际化驶向新征程》，欢迎阅读^^投资要点：“创新+国际化”仍将是2026年板块核心主线。重点关注创新药产业链，景气度预计将持续向上。同时，医疗器械行业阶段性影响因素持续缓和，创新与国际化加速推进，2026年有望迎来改善。中国创新药在新靶点、新技术、新疾病领域的布局已经呈现领先趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224151317a6c92a6e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224151317a6c92a6e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU2399975544.HKD","LU0561508036.HKD","01801","09926","LU0634319403.HKD","IE00B5MMRT66.SGD","LU0417516738.SGD","IE00B543WZ88.USD","LU2476274308.USD","LU0348827113.USD","LU2488822045.USD","02615","09939","06990","ONC","LU0348735423.USD","LU0348767384.USD","LU0348825331.USD","BK1574","LU2476274720.SGD","02268","01530","LU0417516571.SGD","LU1720050803.USD","LU1961090484.USD","LU0348783233.USD","IE00BPRC5H50.USD","LU1794554557.SGD","LU2778985437.USD","LU0540923850.HKD","BK1515","LU0348784397.USD","LU0417516902.SGD","LU0348766576.USD"],"gpt_icon":0},{"id":"2594405085","title":"21专访丨高特佳投资副总经理于建林：锚定下一代疗法 创新药行业走向价值深化","url":"https://stock-news.laohu8.com/highlight/detail?id=2594405085","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594405085?lang=zh_cn&edition=fundamental","pubTime":"2025-12-24 07:00","pubTimestamp":1766530800,"startTime":"0","endTime":"0","summary":"高特佳投资集团副总经理于建林在接受21世纪经济报道记者专访时也指出，中国创新药行业已迈入高质量发展新阶段。于建林进一步表示。2026年港股依旧是中国未盈利创新药企业上市的核心阵地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224070019a6c78236&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224070019a6c78236&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","BK4585","BK4139","ONC"],"gpt_icon":0},{"id":"2592959471","title":"双总裁时代的百济神州 还有哪些故事可讲？","url":"https://stock-news.laohu8.com/highlight/detail?id=2592959471","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592959471?lang=zh_cn&edition=fundamental","pubTime":"2025-12-19 23:31","pubTimestamp":1766158317,"startTime":"0","endTime":"0","summary":"12月19日，百济神州迎来新的人事调整。百济神州发布公告称，公司董事会同意聘任全球研发负责人汪来博士担任百济神州总裁，全球研发负责人。聘任生效后，汪来将担任百济神州总裁，全球研发负责人职务，负责管理百济神州研发、业务拓展以及业务联盟关系管理等职能。此外，百济神州方面还透露，吴晓滨仍然担任百济神州总裁、首席运营官COO，与汪来并列为双总裁。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512193597095415.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512193597095415.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0588546209.SGD","LU1969619763.USD","BK1500","LU1770034418.SGD","BK4585","BK1588","06160","LU1303224171.USD","BK1583","BK4526","BK0239","BK4139","ONC","BK1161","LU0307460666.USD","688235","LU1251922891.USD","LU1719994722.HKD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2591376935","title":"TIGIT抗体再折戟：胃癌三期失败，免疫治疗前路何在？","url":"https://stock-news.laohu8.com/highlight/detail?id=2591376935","media":"药事纵横","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591376935?lang=zh_cn&edition=fundamental","pubTime":"2025-12-16 07:03","pubTimestamp":1765839790,"startTime":"0","endTime":"0","summary":"2025年12月12日，吉利德与Arcus Biosciences联合宣布，其PD-1+TIGIT+化疗一线治疗胃癌的三期临床STAR-221因无效而终止。这是TIGIT抗体赛道又一次重大挫折，也再次引发业界对免疫联合疗法靶点选择与临床策略的深刻反思。PD-1/TIGIT双抗可以同时阻断这两条免疫逃逸通路，恢复T细胞和NK细胞的活性，产生更强的抗肿瘤免疫反应 。PD-1/TIGIT双抗若能在临床试验中取得成功，将有望填补肿瘤免疫治疗领域的空白，满足未被满足的临床需求，市场潜力巨大。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216070651a6a6b74b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216070651a6a6b74b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1303224171.USD","BK1500","BK1588","LU0588546209.SGD","LU1969619763.USD","BK1161","LU2328871848.SGD","LU1719994722.HKD","ONC","LU1770034418.SGD","LU0307460666.USD","LU1251922891.USD","BK1583","06160"],"gpt_icon":0},{"id":"2591697904","title":"午后突发！港股通创新药ETF（520880）跌2.77%创阶段新低，康方生物、百济神州等大权重龙头领跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2591697904","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591697904?lang=zh_cn&edition=fundamental","pubTime":"2025-12-15 13:39","pubTimestamp":1765777140,"startTime":"0","endTime":"0","summary":"12月15日午后，港股通创新药板块加速下跌，港股通创新药ETF一度跌至2.77%创近5个月新低，龙头股齐挫，康方生物跌超5%，百济神州跌逾6%，中国生物制药、信达生物跌超3%。　　阶段新低之际，“抄底”资金或再行动，港股通创新药ETF场内宽幅溢价，显示买盘资金相对强势。　　把握港股创新药低吸窗口期，认准同类最大港股通创新药ETF及其场外联接基金，标的指数恒生港股通创新药精选指数具备三大独特优势：","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-12-15/doc-inhawauf3976382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0348784397.USD","LU1794554557.SGD","BK4585","LU2778985437.USD","LU0348767384.USD","ONC","LU0634319403.HKD","BK1574","LU1303224171.USD","LU2328871848.SGD","LU0348735423.USD","LU0348827113.USD","BK1583","IE00BPRC5H50.USD","LU1719994722.HKD","LU0417516571.SGD","LU0540923850.HKD","06160","LU1969619763.USD","LU1961090484.USD","BK0239","09926","BK1161","IE00B543WZ88.USD","LU0348766576.USD","BK1500","LU1251922891.USD","LU0417516902.SGD","LU0348825331.USD","LU0417516738.SGD","BK4139","LU0561508036.HKD","BK4526","LU2399975544.HKD","LU2476274720.SGD","520880","LU0307460666.USD","LU2488822045.USD","LU0588546209.SGD","LU2476274308.USD","LU0348783233.USD","BK1588","688235","LU1770034418.SGD","LU1720050803.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2590348233","title":"中信证券：医保谈判成功率创近年新高，关注创新药企","url":"https://stock-news.laohu8.com/highlight/detail?id=2590348233","media":"瑞财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590348233?lang=zh_cn&edition=fundamental","pubTime":"2025-12-09 14:57","pubTimestamp":1765263437,"startTime":"0","endTime":"0","summary":"瑞财经 严明会近日，中信证券指出，2025年12月7日，2025创新药高质量发展大会在广州举行，国家医保局现场发布了2025年《国家基本医疗保险、生育保险和工伤保险药品目录》及《商业健康保险创新药品目录》。在基本医保目录上，最终114个成功纳入，其中包含50个1类创新药，成功率为88%，谈判成功率创近7年新高。与此同时，首版商保目录发布，共纳入19款产品，包含5款CAR-T产品。中信证券认为，伴随着国家对创新药持续的政策倾斜和鼓励支持，医保和商保的双轨并行，有望带动支付多元化，创新药企的回报有望逐步提升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512091457209532ed86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512091457209532ed86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","06160","BK4526","BK4139","ONC","02359"],"gpt_icon":0},{"id":"2590348255","title":"药价登记，出海新支点","url":"https://stock-news.laohu8.com/highlight/detail?id=2590348255","media":"药视声Medispace","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590348255?lang=zh_cn&edition=fundamental","pubTime":"2025-12-09 11:58","pubTimestamp":1765252739,"startTime":"0","endTime":"0","summary":"本土龙头企业如恒瑞医药、百济神州等持续投入高额研发费用，其中恒瑞医药已在中国获批上市23款1类新分子实体创新药，覆盖肿瘤、自身免疫等领域。从早期的原料药出口，到现在的创新药License-out，2025年上半年国产创新药对外授权交易总金额已接近660亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209164810a43d48ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209164810a43d48ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","ONC","BK4585","BK4526","01276","BK4139"],"gpt_icon":0},{"id":"2589877119","title":"19种药品纳入首版商保目录，5款CAR-T疗法集体入围，影响有多大？","url":"https://stock-news.laohu8.com/highlight/detail?id=2589877119","media":"澎湃新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589877119?lang=zh_cn&edition=fundamental","pubTime":"2025-12-07 21:37","pubTimestamp":1765114670,"startTime":"0","endTime":"0","summary":"在7日的大会现场，国家医保局相关负责人还为入选商保创新药目录的企业代表颁发了证书。根据此前公布的数据，首版商保创新药目录申报信息共有141份，涉及药品通用名141个，121个通过形式审查，实际参与商保创新药目录价格协商的药品24个。进入商保目录后，公司CAR-T疗法的对外价格还是不变的，但对于保险公司会有一个折扣价格。两款药物均出现在首版目录名单，有望造福更多AD患者。从最终的结果来看，该产品未能进入商保目录。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251207213959a439684c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251207213959a439684c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK4599","LU0154236417.USD","01228","02171","LU1093756325.SGD","BK4007","IE00BZ1G4Q59.USD","06160","BK4532","IE00BKVL7J92.USD","BK4022","NVO","BK4585","BK4230","BK4588","ONC","LU1093756168.USD","688235","02161"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":194,"code":"91000000","status":"200"}]}}